Related Experiment Video

Updated: May 18, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation

Nihar Desai1, Eshrak Al-Shaibani1, Tommy Alfaro-Moya1

  • 1Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Canada; Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.

Transplantation and Cellular Therapy
|May 16, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
GVHDallogeneic hematopoietic cell transplantationprior malignancysecond malignancysurvivorship

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview